Routine sedation of patients has been recommended for many years after coronary thombosis and indeed it has been suggested that patients are undersedated in the early post-infarct period. ' Diazepam is a widely prescribed and safe drug which has been used in the management of the early convalescent phase of myocardial infarct.2 A priori, it seems to be a desirable agent for four reasons. Firstly, it should help the patient through an emotionally traumatic experience,3 at the same time allowing him to rest more completely.
Secondly, a direct antiarrhythmic action has been attributed to the compound in animal experiments and in man.4 5 Thirdly, direct coronary artery vasodilatation by diazepam has been suggested.6 7 Fourthly, by relieving anxiety, there should be a reduction of circulating catecholamine levels and sympathetic autonomic discharge thus reducing the risk of arrhythmias being caused indirectly through these mechanisms.
A double blind controlled prophylactic trial of oral diazepam versus placebo was therefore carried out to determine whether an oral dose of 10 mg qds would reduce the incidence of death or of those tachyarrhythmias defined as requiring treatment.
Patients and methods
One hundred and seventy-two consecutive male patients with suspected myocardial infarction, and without arrhythmias on admission to the coronary care unit at Sheffield Royal Infirmary, were admitted to the trial. Patients too ill to take oral therapy or those having taken tranquillising drugs routinely over the previous month were excluded. Subsequent confirmation of the diagnosis of myocardial infarction depended upon: (1) the development of Q wave or T wave inversion in daily electrocardiograms; and (2) transient rise in the serum creatine kinase (CK) or aspartate transaminase (AST) above hospital normal values. After random allocation (stratifying according to the time interval from the onset of pain) patients received either a white 10 mg tablet of diazepam or a placebo tablet matched for appearance. The first tablet was given on admission and treatment was then continued every six hours before meals for 48 hours when the trial terminated. Other treatment was given as clinically indicated over this time (see Table 6 ) but day-time sedation other than necessary analgesics or antiemetics was to be avoided.
Over the 48-hour period of assessment the following observations were recorded.
(1 Table 6 ). For analysis the distance in inches of the cross from that end denoting mild (or no) symptom or anxiety was measured; this gave a score ranging from 0 to 6 inches (to the nearest tenth of an inch) corresponding to mild and severe symptoms, respectively. Two questions (Q1O relating to double vision and Qll to pain in the fingers and toes) were used in combination to identify patients who were unlikely to report their symptoms reliably. Question 3 (chest pain) is a measure both of a physical symptom and of the patient's anxiety about it, and the two aspects are inextricably linked. 
ARRHYTHMIAS
The groups were also similar in the numbers of patients suffering arrhythmias in this period, and in the distribution of types of arrhythmia (Table 3) . Arrhythmias tabulated are those for which treatment is customarily given; the ventricular extrasystoles were those of 6 beats per minute or more suggested by Lown et al.13 as requiring treatment. In Table 4 the incidence of tachyarrhythmias is compared between the two treatment groups, stratifying according to two factors thought likely to influence this incidence, that is the maximum of the three daily values of CK and the time from infarction to admission to the trial. The diazepam group contained a higher proportion than the placebo group of patients with a maximum value of CK of 600 IU/l or more (who had a high risk of tachyarrhythmia). The data as laid out in this Table 5 , a summary of the monitoring data is given, excluding the four patients who died after only a few hours of monitoring (see Table 2 ). For brevity, heart rate and blood pressure data are summarised for the first 12 hours and for the last 12 hours of the 48-hour period of the trial.
Bearing in mind the sizes of the standard errors of the mean in Table 5 there are no remarkable contrasts, other than in the higher CK and aspartate transaminase levels in the diazepam group. Some of the catecholamine data are not available for analysis, for technical reasons or because there were doubts about the completeness of the "24-hour urine" sample from which they were obtained.
If Table 5 is subdivided (not shown) according to the maximum CK level attained, then among patients with maximum values in the range 0 to 299 IU/1, the mean systolic and mean diastolic blood pressures during the first 12 hours were each significantly higher* for 25 such diazepam patients (149/95 mmHg) than for the same number of controls (133/87 mmHg). However, further analysis shows that these figures simply reflect mean blood pressures on admission which were higher among these 25 diazepam patients.
SYMPTOMS AND ANXIETY LEVELS
For 53 patients on diazepam and 50 on placebo, suitable records of self-assessment of symptoms and anxiety were available (Table 6 ). Among the records excluded were those of three patients on diazepam who were too drowsy to complete them and those of three further patients (also on diazepam) who claimed double vision (Q10) and pain in their fingers and toes (Q 1 ). As Table 6 shows, these two symptoms were unimportant (regardless of treatment group or day), as indicated by the small numbers of patients reporting them (five to 10) and the low median scores (0 7 to 1 3) among those few patients. Palpitation (Q2) was not common in either treatment group though when reported it was severe on day 1. Most symptoms were less common and/or less severe on day 2 than on day 1. Among the placebo patients, however, 10 more were preoccupied with their heart (Q4) on day 2 (42) than on day 1 (32), and among the diazepam patients it was the same number (31) on the two days. In each treatment group on each day over three-* Student's two-sample t tests: systolic BP: t=3-14, df=48, p < 001; diastolic BP: t = 2-69, df =48, p < 0O5. quarters of the patients were worried about what on day 2 than became more sleepy (p < 0 05), and had happened (Q5), about a third admitted to being there was also a significant difference between the frightened (Q6), and about half were tense (Q7). treatment groups in the distribution of patients Chest pain (Q3) was reported on day 1 by half among the three categories-"improved", "deteriothe placebo group and two-thirds of the diazepam rated", "unchanged" (X2 =6&03: p <005), indicatgroup; on day 2 fewer patients reported the symptom ing less rapid recovery with diazepam. and it was less severe, and for the diazepam group there were significantly more patients whose chest OTHER FINDINGS pain improved than whose pain deteriorated Serum levels of diazepam and of its active metabolite (p <0.01). In both treatment groups drowsiness desmethyldiazepam were measured in a randomly (Q9) was reported by over two-thirds of patients selected subgroup of 24 of the patients on diazepam. on each day but was more severe in the diazepam The mean level of diazepam was 149 ng/ml and the patients: when the entire groups were compared by mean level of desmethyldiazepam 88 ng/ml. the Mann-Whitney test,'5 the distribution of Although the trial procedure requested that drowsiness scores was significantly more severe in sedatives should not be prescribed, about half the the diazepam group, both on day 1 (p < 0 05) and patients on diazepam and on placebo were given a even more so on day 2 (p < 0 001). In the placebo sedative (Table 7) , usually prochlorperazine, as an group significantly more patients became less sleepy antiemetic, and/or nitrazepam at night. If anything, group.bmj.com on June 14, 2017 -Published by http://heart.bmj.com/ Downloaded from Table 6 Self-rating symptom and anxiety Mann-Whitney U test (Siegel"', p 116 ff) for comparison of entire diazepam group with the entire placebo group on same day: *, P < 0 05-t, P < 0-001. Sign test (Siegel", p origin and therefore less accessible to a central psychotropic action. There was a suggestion from the maximum CK and AST levels attained that the two groups may not have been comparable in the severity of their infarcts on admission to the trial, but corrections were made for this in the analysis.
Other monitored data including heart rate, blood pressure, and tachyarrhythmias showed no consistent differences (though the one minute in 15 sampling procedure is likely to underestimate the number of tachyarrhythmias, to the same extent in each treatment group, in contrast to the semiautomated analysis of continuous recordings for which equipment is now commercially available). On the whole, therefore, the treatment groups were similar in the monitored physiological and biochemical data.
The important difference between this study and that of Melsom et al.," apart from the use of double-blind controls, is that they used an intravenous loading dose of diazepam, while we did not. It is difficult to compare serum levels of diazepam and of its active metabolite between the studies since they took repeated blood samples over 72 hours (finding accumulation over this time), whereas in this study serum was taken at the end of the first 24-hour period only for a random sample of 24 patients.
Thus, apart from the possibility that diazepam could be responsible for small increases in CK levels, we did not observe any major unwanted side effects. However, it seems unlikely that any major beneficial effect other than sedation accrues from the use of diazepam in the post-myocardial infarction state. In particular, the half to two-thirds reduction in the incidence of tachyarrhythmias which the trial was capable of detecting was not found. 
